Product Pipeline
12/21/1998 Corixa Corporation obtains worldwide exclusive license to leukemia antigen company plans to use WT1 to develop therapeutic vaccines for leukemia and lymphoma
12/17/1998 Stanford Rook Holdings PLC and Corixa Corporation sign agreement in autoimmune diseases
12/13/1998 Corixa Corporation to acquire Anergen, Inc.
Company extends product portfolio to include additional therapies for prevention and treatment of autoimmune diseases
11/09/1998 Corixa reports third quarter results
11/05/1998 Corixa and ImmGenics form collaboration to develop antibody-based immunotherapeutics and immunodiagnostics
10/28/1998 Corixa and SmithKline Beecham Biologicals sign strategic partnership
Agreement is a major expansion, adding five new vaccine programs to existing discovery efforts
09/16/1998 Corixa Corporation completes acquisition of GenQuest, Inc.
Company adds non-vaccine expertise to complement its antigen discovery and growing antibody programs
09/08/1998 Corixa Corporation announces issuance of patent for Muc-1 peptide vaccines
08/10/1998 Corixa reports second quarter results
08/07/1998 Corixa announces extension of vaccine adjuvant research agreement and option agreement with Pasteur Merieux Connaught (Rhone-Poulenc Group)
08/07/1998 Corixa and SmithKline Beecham Biologicals extend tuberculosis collaboration
06/23/1998 Corixa to acquire GenQuest
05/18/1998 Corixa Corporation announces research progress with Her-2/neu vaccine
Early results indicate induction of immune response
05/11/1998 Corixa reports first quarter results
04/24/1998 Corixa Corporation and CellPro, Incorporated agree to terminate license and research collaboration
04/14/1998 Corixa announces option to license marker for breast carcinoma
04/07/1998 Corixa Corporation establishes diagnostics collaboration with Imugen
03/16/1998 Corixa Corporation announces issuance of patent for diagnosis of Her-2/neu positive tumors
02/23/1998 Corixa reports fourth quarter and year end results
02/17/1998 Corixa extends antigen discovery agreement with SmithKline Beecham
01/05/1998 Corixa announces extension of vaccine adjuvant research agreement and option agreement with Pasteur Merieux Connaught
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Current and archived company press releases.